Moreover, beyond NSCLC, aberrant EGFR signaling also manifests in colorectal cancer and head and neck cancer.[38] Patients with EGFR overexpression in colorectal and head and neck cancers are commonly treated with the EGFR monoclonal antibody cetuximab. The gene discussed is EGFR; the disease is head and neck cancer.